Status:
COMPLETED
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Tanabe Pharma Corporation
Conditions:
Non-erosive Reflux Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the pharmacodynamic effect of omeprazole n a Japanese non-erosive reflux disease population
Eligibility Criteria
Inclusion
- Patients who identified their predominant symptom as heartburn and were classifiend as Grande M or N according to Hoshihara's modofied version of Los Angeles Classification at esophagogastroduodenoscopy. Written informed consent, ability to comply with study instructions
Exclusion
- Patients with any ongoing gastrointestinal bleeding at the time of esopgahogastroduodenoscopy, patients with any history of erosive esophagitis or any other major diseases or concommittant drugs likely to interfere with the evaluation of this study
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2004
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00259051
Start Date
January 1 2004
End Date
August 1 2004
Last Update
January 24 2011
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Ashahikawa, Japan
2
Research Site
Fukuoka, Japan
3
Research Site
Hiroshima, Japan
4
Research Site
Ichihara, Japan